- Home
- Publications
- Publication Search
- Publication Details
Title
Physiologically Based Pharmacokinetic Modeling of Palbociclib
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 57, Issue 2, Pages 173-184
Publisher
Wiley
Online
2016-07-12
DOI
10.1002/jcph.792
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The impact ofCYP3A5*3polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model
- (2015) Chie Emoto et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity
- (2015) Kayode Ogungbenro et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- (2015) J. A. Beaver et al. CLINICAL CANCER RESEARCH
- Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA
- (2015) Christian Wagner et al. CLINICAL PHARMACOKINETICS
- Palbociclib: First Global Approval
- (2015) Sohita Dhillon DRUGS
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation
- (2014) Chuang Lu et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Predicting the Effect of Cytochrome P450 Inhibitors on Substrate Drugs: Analysis of Physiologically Based Pharmacokinetic Modeling Submissions to the US Food and Drug Administration
- (2014) Christian Wagner et al. CLINICAL PHARMACOKINETICS
- Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data
- (2013) Nikolaos Tsamandouras et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations
- (2013) Vicky Hsu et al. CLINICAL PHARMACOKINETICS
- Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure
- (2013) Karen Rowland Yeo et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro Data
- (2013) Fumiyoshi Yamashita et al. PLoS One
- Physiologically Based Pharmacokinetic (PBPK) Modeling in Children
- (2012) J S Barrett et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- (2011) G K Schwartz et al. BRITISH JOURNAL OF CANCER
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Prediction of time-dependent CYP3A4 drug–drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover
- (2011) K. Rowland Yeo et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Effect of Different Durations and Formulations of Diltiazem on the Single-Dose Pharmacokinetics of Midazolam: How Long Do We Go?
- (2011) Evan J. Friedman et al. JOURNAL OF CLINICAL PHARMACOLOGY
- In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype
- (2010) Dinko Rekić et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance
- (2010) Trevor N. Johnson et al. CLINICAL PHARMACOKINETICS
- Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review
- (2010) P Zhao et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors
- (2010) Y.-H. Wang DRUG METABOLISM AND DISPOSITION
- Prediction of Modified Release Pharmacokinetics and Pharmacodynamics from In Vitro, Immediate Release, and Intravenous Data
- (2009) Viera Lukacova et al. AAPS Journal
- Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite
- (2009) X. Zhang et al. DRUG METABOLISM AND DISPOSITION
- The Simcyp®Population-based ADME Simulator
- (2009) Masoud Jamei et al. Expert Opinion on Drug Metabolism & Toxicology
- Cytochrome P450 Turnover: Regulation of Synthesis and Degradation, Methods for Determining Rates, and Implications for the Prediction of Drug Interactions
- (2008) Jiansong Yang et al. CURRENT DRUG METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now